KPG-818 for Patients with Hematologic Malignancies
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

KPG-818 for Patients with Hematologic Malignancies

Sponsor: Kangpu Biopharmaceuticals, Ltd.

Protocol KPG-818-HEM-101. A phase 1 study of lenalidomide analog KPG-818 in subjects with hematologic malignancies. Included diagnoses are: multiple myeloma, mantle cell lymphoma, follicular lymphoma, diffuse large b-cell lymphoma, adult t-cell leukemia-lymphoma, chronic lymphocytic leukemia, and indolent lymphomas.